摘要
目的探讨依达拉奉联合低分子肝素钙治疗进展型脑梗死的临床效果。方法将142例进展型脑梗死患者随机分为观察组和对照组,各71例,两组患者均给予常规对症治疗,对照组加用依达拉奉治疗,观察组加用依达拉奉联合低分子肝素钙治疗,观察两组患者的临床效果。结果观察组患者治疗后的NIHSS评分明显低于对照组(P<0.05),基本治愈率及总有效率分别为36.62%、90.14%,均明显高于对照组的11.27%、69.01%(P<0.05)。结论依达拉奉联合低分子肝素钙治疗进展型脑梗死具有效果好、神经功能改善明显等优点,且安全性较好。
Objective To discuss the clinical effect of edaravone combined with low molecular heparin calcium treating progressive cerebral infarction. Methods 142 patients with progressive cerebral infarction were equally divided into the observation and the control groups.Both groups received conventional Symptomatic treatment,and the control group was additionally provided with edaravone,while the observation group was offered edaravone combined with low molecular heparin calcium.The treatment effect of patients in the two groups was observed. Results NIHSS score in the observa- tion group was visibly lower than that in the control group after treatment （P〈0.05）,the basic cure rate and the total ef- fective rate in the observation group （36.62%,90.14% respectively） was obviously higher than that in the control group （11.27%,69.01% respectively） （P〈0.05）. Conehmion Edaravone combined with low molecular heparin calcium treating progressive cerebral has advantages of good effect,obvious improvement of neurological etc with good safely.
出处
《中国当代医药》
2014年第10期77-79,共3页
China Modern Medicine
关键词
进展性脑梗死
依达拉奉
低分子肝素钙
神经功能
Progressive cerebral infarction
Edaravone
Low molecular heparin calcium
Neurological function
